Fig. 3
Potential adverse effects of LXR agonists and next steps. Systemic administration of LXR agonists may cause neutropenia and lipogenesis related adverse effects such as hyperlipidemia and hepatic steatosis. Investigations in regional drug delivery, LXRβ selective agonists, natural ligands and LXR downstream gene specific treatment may help alleviate the adverse effects and promote the clinical translation. FAS fatty acid synthase, IDOL inducible degrader of low-density lipoprotein receptor, SCD1 stearoyl-CoA 9-desaturase, SREBP1c sterol regulatory element-binding protein 1c